# GLP-1 Drugs Like Ozempic Linked to 30% Lower Breast Cancer Risk in 111,000-Woman Study

*2026-06-07 10:03 UTC · Science · 1 min read*

> A 111,646-woman study presented at ASCO 2026 found those taking GLP-1 drugs like Ozempic were about 30% less likely to develop breast cancer.

Women who take GLP-1 weight-loss and diabetes medications were about 30% less likely to develop breast cancer, according to a large new study presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and published in JCO Oncology Practice. Researchers reviewed health records of 111,646 women aged 45 to 80 with a body mass index of 25 or above; the roughly 13.7% who had been prescribed GLP-1 drugs such as semaglutide-based Ozempic and Wegovy showed markedly lower breast cancer incidence.

The reduction was about 35% across the full population and 30.5% in a closely matched analysis. Lead author Dr. Elizabeth McDonald of the University of Pennsylvania Perelman School of Medicine cautioned that the study is observational and cannot prove the drugs caused the drop, but said it adds to growing evidence that GLP-1 medications deserve investigation as cancer-prevention tools.

With obesity a known breast cancer risk factor, the team is planning a multisite clinical trial to test whether GLP-1 drugs can actively lower breast cancer rates in high-risk women.

## Sources

- [sciencedaily.com](https://www.sciencedaily.com/releases/2026/06/260605023400.htm)
- [usnews.com](https://www.usnews.com/news/health-news/articles/2026-06-03/glp-1-drugs-like-ozempic-may-lower-breast-cancer-risk-by-about-30)

---
TechTools News · https://techtools.cz/tools/news/article/1788-glp-1-drugs-like-ozempic-linked-to-30-lower-breast-cancer-risk-in-111-000-woman
Česká verze: https://techtools.cz/tools/news/clanek/1861-leky-typu-ozempic-glp-1-spojeny-s-o-30-nizsim-rizikem-rakoviny-prsu-ukazala